[18-F] Florbetaben..........T228

[18-F] Fluortriopride..........M254

[18F]ASEM..........M7

[18F]-FEPPA..........32.2

1H-MRS..........60.3, M165

22Q11..........19.4

22q..........11.2 CNVT196, T203

5C-CPT..........T198

5CSRTT..........M146

5-Ht1B..........W65

5-Ht2A Receptor..........W27, W244

5HT2A receptors..........T170, W46

7-DHC..........W51

ABCD..........28.3

Abstinence..........14, M229, M245, W229

Abuse..........W234

Abuse Liability..........M220

Abuse Potential..........T166

Acculturation Stress..........W276

Accumbens..........14.2

Acetylcholine..........9.1, T217, W45

Acetylcholinesterase Inhibitors..........W47

Acoustic Startle Response..........T215

Actigraphy..........2.1, 21.4

Action-Outcome Associations..........W178

Acute Effects..........M252

Acute Stress..........9.3, 30.4, 53, M105, T5, T7, T15, W21, W120, W121, W130, W144, W272

Adaptive Deep Brain Stimulation..........18.3

Addiction..........12, 12.2, 20.2, 20.4, M140, M272, T49, T238, T240, T244, T264, T279, W225, W231, W249, W260, W262, W267, W280

Addiction Circuitry..........M236, M263, W278

Add-On Treatment..........44.1

Adenosine A2A Receptor..........M66

Adiponectin..........16.4

Adolescence..........6, 6.2, 6.3, 6.4, 11, 11.1, 23.1, 28.2, 28.3, 29.3, 40.1, 40.2, 40.3, 40.4, 48.1, 48.3, M33, M34, M35, M38, M48, M61, M227, M230, M267, T20, T81, T93, W35, W38, W40, W58

Adolescent..........27.2, 28, T86

Adolescent Academic Performance..........W271

Adolescent Alcohol..........M233, W247

Adolescent Anxiety..........M26, M36, M143

Adolescent Binge Drinking..........T48

Adolescent Brain and Cognitive Development..........6.4

Adolescent Brain and Cognitive Development Study..........28.1, 28.3

Adolescent Depression..........11.2, M36, M37, M40, M106, T88, T137, W33, W90, W123, W147

Adolescent Development..........6.1, 23.3, 48.4, M168, T43

Adolescent Stress..........M268

Adolescents..........5.2, 40, M49, T95

Adult Hippocampal Neurogenesis..........M40, M116, M120, T174

Adult Onset..........T204

Advance Care Planning..........T168

Adverse Childhood Experiences..........T13

Adversity..........29, 29.3

Advocacy..........62

Aerobic Exercise..........M267

Affect of Adverse Events on Efficacy..........M210

Affect of Adverse Events on Functioning..........M210

Affective Components of Pain..........43, 43.1

Affective Disorders..........M102

Age of Onset..........M188

Aggression..........38, 38.1, 38.2, 38.3, 38.4, M67, M153, M218, M246, T19, W66

Aging..........M4, M7, T1, T26, T56, T57, T176, W2, W110

Aging and Dementia..........M50, M53, T59

Agonist Maintenance..........35.3

Alcohol..........50.3, 54.1, M3, M246, M260, M268, T20, T55, T259, T277, T278, W248, W271

Alcohol and Substance Use Disorders..........50.4, M241, M264, M271, T242, T258, W238, W243, W244, W245, W249, W272

Alcohol Consumption..........59, T232, T262

Alcohol Dependence..........54, 54.2, 54.3, M255, T52, T243, W237, W267

Alcohol Drinking..........59.3, T255, T269, W248

Alcohol Intake..........12.3, 59.2

Alcohol Self-Administration..........59.4, M233, T249, W245

Alcohol Sensitivity..........T232, T280

Alcohol Use Disorder..........59.3, M212, M230, T47, T249, T251, T266, T270, W242, W245, W260, W280

Alcohol Withdrawal..........M269, T265, W253

Alcoholism..........59.1, M143, M144, M244, T254, T275, T281, W280

Alcohol-Seeking Behavior..........M66, T247

ALKS 5461..........W119

Allopregnanolone..........M34

Allostatic Load..........46

Allosteric Modulator..........T257

Alpha Oscillation..........36.1, M47, W126

Alpha-7 Nicotinic Acetylcholine Receptor..........M7, T19

ALS..........T160

Alternative Splicing..........59.1, T36

Alzheimer's Disease..........46.2, M51, M54, T16, W1, W49, W165

AMPA..........M76, M128, W219

AMPA Glutamate Receptors..........T101

AMPA Receptors..........37.3, W91, W219

AMPA TARP Gamma..........8W91

Amphetamine..........T18, T237, W29, W206

Amygdala..........29.1, 53.1, 53.4, 55.3, M10, M13, M65, M114, M134, T15, T22, T48, T72, T82, T125, T150, T194, T277, W7, W39, W52, W74, W96, W114, W123, W171, W235

Amygdala-Hippocampal Differences..........M172

Amyloid..........M5, W48

Analgesia..........M232, T124, W281

Anandamide..........41.1, 41.3, T5

Anatomical Connectivity..........W32

Anesthesia..........T144

Angiogenesis..........M164

Anhedonia..........17.3, M22, M251, T49, T122, W114, W133

Animal Model..........8, 20.3, 29.1, 38, 38.2, 62, M247, T35, T84, T171, T222, T272, W78, W115, W154, W180, W246

Animal Research..........62

ANK3..........T23

Ankryin-G..........M177

Anorexia Nervosa..........T104, W54, W58, W59

Anterior Cingulate..........W203

Anterior Cingulate Cortex..........M146, M278, T93, T248

Anterograde Tracer..........M45

Anthranilic Acid..........T192, W176

Antidepressant..........10.4, 49, 57.2, 57.3, M71, M98, M99, M100, M118, M124, M130, T75, T82, T111, T146, W24, W79, W107, W127, W129, W139, W147

Antidepressant Agents..........W118

Antidepressant Response..........W103

Antidepressant Therapies..........30.4

Antidepressant Treatment Practice..........57.4

Antidepressant Trials..........10.1, W76

Antipsychotic..........52.1, M217, T189, T209, W204

Antipsychotic Induced Weight Gain..........W210, W218

Antipsychotic Medication..........47.4, M54

Antipsychotic Response..........M167

Antipsychotic Treatment..........61.2, M200, T184, T214, W172

Antipsychotic-Associated Obesity..........W30

Antipsychotic-Naïve First-Episode Schizophrenia..........52, 52.2, 52.4, 58.3, M167, T45, T188

Antipsychotic-Naive Schizophrenia..........M179

Antipsychotics..........7.4, M207, M212, T41, T184, W127, W187, W199

Antisocial Personality Disorder..........T180

Anxiety..........4.3, 29.3, 30, 48.1, 55.3, M8, M10, M13, M73, M120, M137, M145, T2, T7, T14, T20, T49, T62, T63, T69, T72, T116, T121, T167, W7, W11, W24, W39, W48, W94, W115, W122

Anxiety Circuitry..........4.2, 30.3, 55.4, M17, M23

Anxiety Disorders..........41.2, T157, W15, W23

Anxious Depression..........T62

APOE..........T228

App..........39

Apparent Diffusion Coefficient..........M156

Appetitive Hormones..........T246

Approach/Avoidance..........M127, M151, W131

Aripiprazole..........M199, W51, W189

Aromatase..........44.2

Artefact Removal..........W256

Arterial Spin Labeling..........M150

Artificial Learning..........W271

Aspirin..........M216, T29

Assessment..........T206

Associative Learning..........W275

ASSR..........W192

Astrocyte..........58.1, M100, W261

Attachment..........29.1, W155

Attention..........M197, T4, T83, T93, T198

Attention Deficit Hyperactivity Disorder (ADHD)..........11.3, M67, M142, M158, T9, T74, T108, W28, W55, W252

Attentional Bias Modification..........M57

Atypical Antipsychotic Drug..........W221

Atypical Antipsychotics..........T206, W212

Auditory..........19.3, T199

Auditory Cortex..........56.1

Auditory Deficits in Schizophrenia..........T205

Auditory Hallucinations..........36.1, T42, T207, W191

Auditory Processing..........T40

Auditory Short-Term Memory..........T205

Augmentation..........51.1

Autism Spectrum Disorder..........1.3, 8, 22.1, 56.4, M39, M47, M92, M147, M148, M150, M158, M164, M204, M213, M215, T76, T83, T85, T86, T90,T92, T173, T203, W32, W37, W41, W42, W43, W180, W143, W150

Autoimmune Encephalitis..........W163

Automated Facial Affect Recognition..........18.3

Autonomic Nervous System..........22.3, W272

Autophagosome..........M203

Autoradiography..........T193

Aversive Conditioning..........T68

Axon Guidance Molecule Genes..........6.1, W149

Axons..........M177

Baby-Cry..........M266

Balb/C Mouse..........W143

Bariatric Surgery..........M56, T164, W61

Basal Ganglia..........M273, T238

Basolateral Amygdala..........M145, M277, T273, W11, W154

Bath Salts..........W230

Bayesian Inference..........12.2

Bayesian Modeling..........M151

BDNF..........38.3, M131, M132, M217, M224, T39, T79, T146, T178, W156

BDNF Delivery..........T97

BDNF Val..........66Met..........W72

Bed Nucleus Of The Stria Terminalis..........30.3, 55.2, 55.4

Behavior..........T30, T92

Behavioral Analysis..........T7

Behavioral Disturbances..........M54

Behavioral Economics..........M89

Behavioral Inhibition..........37, W7

Behavioral Pharmacology..........M247, W236, W251

Benzodiazepine..........M239, W122, W258

Benzodiazepine Diversion..........W258

Benzodiazepine Use Disorder..........W258

Beta-Amyloid Peptide 1-42..........T228

Big Data..........7.2

Binge Eating Disorder..........M57, M62, T103, W55

Bioenergetic..........W213

Bioinformatics..........M99, T117, W215

Biomarker..........1.3, 2, 2.4, 6, 7, 7.3, 7.4, 10, 10.4, 15, 47, 49.2, 52, 52.3, 56.2, 56.4, 57, 58.1, M9, M15, M111, M170, M172, T1, T27, T33, T169, T253, W23, W191, W144

Biotype..........M172, W211

Bipolar..........T221, W211

Bipolar and Unipolar Depression..........T133

Bipolar Depression..........M101, W81, W140

Bipolar Disorder..........5, 5.1, 11.4, 21, 21.1, 33.3, 33.4, 60.1, M4, M70, M78, M81, M92, M102, M115, M119, M123, M190, M206, T23, T24, T25, T29, T78, T108, T112, T118, T119, T123, T135, T140, T150, T153, T202, T219, W78, W85, W96, W110, W111, W112, W227

Bipolar I Depression..........T75

Bipolar I Disorder..........5.3, W190

Blast..........M157

Blood..........52.3

Blood Plasma Analyte..........13.1

Blood Pressure..........M153

Blood-Brain Barrier..........M178, W84

BNST..........55.3, T72

Bodies..........T104

Body Dysmorphic Disorder..........T104

Body Perception..........W226

Body Weight..........W49, W118

Bold Imaging..........T64, T126, T187

Borderline Personality Disorder..........W170

Botox..........W79

Brain..........44.2, W263

Brain Based Markers for Depression..........M126

Brain Connectivity..........49.3, M112, T248

Brain Development..........6.3, 11.4, 23.2, 23.3, 27.1, 28, 28.4, 29, 29.3, 55.3, M22, T91, T105, W39, W66, W243

Brain Glucose Metabolism..........T281

Brain Imaging..........7, 10.2, 33.1, M44, M127, M259, W60

Brain Networks..........7.2, 49.3

Brain Stimulation..........36.1, M59, W37

Brain Stress..........T257

Brain Structure..........T30, T227

Brain Transcription..........10.3, M236

Brain Volume..........M25, M257, T17

Brain Wiring..........T154

Breast Cancer..........W71

Breast Cancer Chemotherapy..........T167

Brexanolone..........W116

Brexpiprazole..........M208, M210, M211

Bulimia Nervosa..........T102, W56

Buprenorphine..........35.1, M77, W94

Buprenorphine-Naloxone..........35.2, 35.3, M225

CACNA1C..........W169

Calcium..........W169

Calcium Imaging..........W65, W75, W155, W262

Calthrin Nanoparticles..........T97

cAMP Signalling..........T146

Cancer..........32, 32.1, W3

Cancer Quality of Care..........T168

Cancer Survival..........T58

Cannabidiol..........M152

Cannabinoids..........T70, T199, W231, W234, W236

Cannabis..........41.1, M201, T236, T268, W246, W264

Cannabis Dependence..........41.4

Cannabis Use..........M141, M219, T43, T55, T274, W265

Cannabis Use Disorder..........41, M226, M282

Cardiac Autonomic Tone..........T73

Cardiolipin..........M115

Cardiometabolic Risk..........W30

Cardiovascular..........M87, M253

Care Coordination..........M225

Cariprazine..........T152, W81, W189

Catecholamine Depletion..........M58

Cats/Foxes..........W166

Caudate..........M161, W34, W203

Causal Modeling..........M21

CB1 Receptor..........M277

CBT..........T3, W17

Celecoxib..........M101, T135, T140

Central Amygdala..........9.2, 14.4, 30.2

Central Autonomic Network..........T73

Central Nucleus of the Amygdala..........55.2, 55.4

Cerebellum..........M264, T34, W150, W194

Cerebral Blood Flow..........M150

Cerebrospinal Fluid..........13, 13.3, 20.1, T96

C-Fos..........W279

C-Fos-Expressing Ensembles..........50.1

Chemogenetics..........30.1, 37.2, M48, W62, W266

Chemokine..........58.3

Child Maltreatment..........M32

Childhood..........T165

Childhood Adversity..........29.4, W177

Childhood Maltreatment..........29.1, T113

Childhood Onset Bipolar Disorder..........T125

Childhood Trauma..........29.4, M37, M42, M46, T28, T207, T274

Childhood Urban-Rural Upbring..........M171, M184

Childhood-Onset Schizophrenia..........M174

Children..........11, 22, T10, T41

Children and Adolescents..........28.1, 28.4, M67, T9, T14, W6, W26, W39

Choice..........T243, T276, W251

Cholesterol Biosynthesis..........T278, W51, W88

Cholinergic Function..........W45

Cholinergic System..........T252

Chorioamnionitis..........22.4

Choroid Plexus..........20.1

Chronic Food Restriction Stress..........W59

Chronic Pain..........25, W227

Chronic Pain Treatment..........25.3, 43, 43.2, T166

Chronic Social Defeat..........M126

Chronic Stress..........17.1, 30.4, 53, M24, M120, T15, T59, T148, T217, T273, W36, W84, W117, W121, W130, W144

Cingulo-Opercular Network..........T13

Circadian Function..........40.3

Circadian Rhythm..........21, 21.4, 40, 40.1, 40.4, M221, T153, T210, T244, W96, W214

Circuit..........6.1, 24.1, 42.1

Circuit Mapping..........M182, M240

Circular RNA..........20, 20.3

Circulating miRNA..........20.1

CLARITY..........W185

Claustrum..........W134

Clinical High Risk..........13, 19.2, T197, W179, W182, W222

Clinical High Risk for Psychosis..........M165, M201

Clinical Outcome Prediction..........33.4

Clinical Trial..........2.4, 44, M79, M149, M175, M212, M255, T6, T40, T41, T159, T269

Clinical Trial Rating Methods..........W139

Clinician Reported Outcomes..........W76

Clozapine..........M183, W221

Clustering..........49.3, M243, T89, W260

CNS Antibody Delivery..........T96

CNS Clinical Trials..........M51, T103

CNTNAP2..........W42

Co-Abuse..........M260

Cocaine..........37, 50.3, M270, T51, T53, T229, T230, T231, T261, T271, T279, T282, W261, W273, W279

Cocaine Addiction..........20.3, 37.2, 37.3, 50.2, M63, M247, M251, M253, M254, T248, T250, W229, W269

Cocaine Seeking..........14, M229, M238, M277, W268, W274

Cocaine Self-Administration..........M236, M237, M267, T273, W240

Cognition..........2.4, 6, 19, 24.2, 24.4, 32.1, 32.3, 36.2, 42.2, 46.2, M79, M159, M168, M169, M206, T34, T39, T57, T163, T167, T191, T213, T223, T227, T256, W50, W121, W141, W145, W182, W188, W202, W209, W220, W264

Cognitive Aging..........M5

Cognitive Behavioral Therapy..........M161, T87, T143, T218, W26

Cognitive Control..........M117, M186, M192, M227, M245, T13, T83, T105, T106, T118, W201

Cognitive Control Network..........T86

Cognitive Decline..........M206, W3

Cognitive Deficits..........22.4, 52.2

Cognitive Enhancement..........31.1, M6, T182, W145, W184

Cognitive Flexibility..........59.4, W8

Cognitive Function..........T272, W49

Cognitive Functioning..........31, M274, T182, W172

Cognitive Impairments..........36, M195

Cognitive Neuroscience..........M40, M68

Cognitive Phenotypes..........26, T37, W74

Cognitive Reappraisal..........W138, W170

Cognitive Remediation..........M218, W173

Cognitive Symptoms..........M170

Cognitive Training..........24.2, 36.3

Cognitive/Emotional Task Performance..........M117, W13

Colony Stimulating Factor-1..........T148

Combat Veteran..........51.4, T64

Comparative Neuropsychopharmacology..........M274

Comparative Studies..........M181

Compulsive Behavior..........12.3, W18

Compulsive Models of Drug Use..........T255

Compulsivity..........T242, T243

Computational Modeling..........12, M245, T106, W63, W131

Computational Psychiatry..........33.1, 57.4, M259, T14, T63, W133, W137

Computerized Cognitive Training..........T40

Concussion..........T64

Conditioning..........M273

Connectivity..........7.2, 27, M9, M19, M94, M124, T104, T130

Connectome..........23, W17

Consciousness..........3.3

Contingency Management..........14.4

Controlled Substance Scheduling..........T166

Correlates..........61.1

Correlation Network..........13.1

Cortex..........M201, W134

Cortical Circuit Function..........M182, M186, M204

Cortical Excitability..........T176

Cortical Excitation-Inhibition Balance..........19.2, M72, T23

Cortical Inhibition..........M72

Cortical Neurons..........M194

Cortical Plasticity..........60.1

Cortical Regulation..........37.2

Cortical Thickness..........T163, T188, W205

Cortical Thinning..........13.2

Corticolimbic..........M45

Corticosteroids..........22.1, W161

Corticosterone..........T226, W143

Cortico-Striatal Circuit..........W63

Corticostriatal Connectivity..........27.3, T154, W149

Corticostriatal Networks..........T107

Corticotropin-Releasing Factor (CRF)..........9, 9.1, 9.2, M142, M246, T66, T257

Corticotropin-Releasing Hormone (CRH)..........9.3, W114

Cortisol..........22.3, 51.4, M21, M38, T132, W59, W100, W120

CPP..........M248

Craving..........12.2, 12.4, M263, T251

C-Reactive Protein..........M93

Creativity..........M119

CRF-R1..........9.2, M8

CRISPR/Cas..........945, M92, W86

Cross Generational Transmission..........W265

CRP..........M3

CSF Biomarkers..........T96, T177, W41

Cue Reactivity..........50, 50.3, 50.4, M223, M238, M263, W67

Cue Reinstatement..........M261, W278

Cue-Induced Craving..........50.2, M263, W246

Cuprizone Short-Term Exposure..........W217

Cyclic AMP..........T175

Cytochrome P450s..........M69, W127

Cytokine..........8, 22, 54.3, M93, M129, M164, M204, M213, M215, M257, T84, T149, W84, W128

Cytoskeleton..........M203

D1 Dopamine Receptors..........31, 31.1, 31.2, 31.3, T34, T234, W162, W193, W194

D2 Dopamine and 5HT2A Serotonin Antagonists..........W46

D2 Receptor..........M207, T53, W5, W134

dACC..........33.1, M26, T107

Dasotraline..........T103

Data Fusion..........W256

Data Quality..........M175

D-Cycloserine..........T87, W9, W26

De Novo Mutation..........T76

Decision-Making..........31, M65, M89, M151, M259, T276, W235

Deep Brain Stimulation..........18.2, 18.3, M110, T128, W8

Default Brain Network..........38.4

Default Mode Network (DMN)..........12.4, 17.4, M56, M256, T89, T179

Deficit Syndrome..........T195

Delay Discounting..........M272, W62

Delirium..........W44

Delta..........9-Tetrahydrocannabinol..........T43

deltaFosB..........M107

Dementia..........T160, T170, W47, W45, W48

Dementia-Related Psychosis..........W46

Dendrites..........T142

Dendritic Remodeling..........T217

Dendritic Spine..........M236, T93, T183, W207

Dentate Gyrus..........M84, T19, T174, W10

Depression..........2.2, 2.3, 10.1, 10.3, 17.4, 24, 33.1, 33.2, 40.2, 43.1, 48.1, 53.3, 57, 57.4, M22, M53, M71, M73, M75, M76, M80, M83, M89, M94, M107, M109, M115, M118, M120, M122, M127, M128, M129, M130, M132, T11, T116, T21, T27, T28, T30, T151, T69, T77, T80, T114, T120, T121, T126, T127, T130, T134, T136, T138, T167, T266, W4, W22, W38, W75, W78, W82, W94, W98, W104, W108, W112, W113, W115, W122, W126, W133, W135, W139, W142

Depression Inflammation Cytokine..........M114

Depression Risk..........W86

Depression Subtypes..........49.4, M125, W89

Depression Treatment Response..........10, M86, T129

Depressive Symptoms..........M93

Desensitization..........W193, W233

Design..........23

Desvenlafaxine..........M82

Development..........23.1, 28.3, M190, T12

Developmental..........22

Developmental Neuroscience..........T90, W188

Developmental Psychopathology..........23.3, 27.1, 28, 29, M143, T250

Developmental Trajectories..........6.2, 11.2

Dextromethorphan/Quinidine..........M274

DHCR7..........W51

Diagnosis..........T75, W163

Diet Induced Obesity..........32, T98, T99, W118

Dietary Supplement..........W228

Dieting..........M60

Diffusion MRI..........T37, T154

Diffusion Tensor Imaging (DTI)..........32.1, M45, M155, M165, T66, T88, T94, W4, W17, W32, W33, W136, W202

Diffusion Weighted Imaging..........7.1, M198

Digital Assessment..........T122

Digital Health Feedback System..........57.4

Dimensional..........M133

Dimensions of Psychosis..........T207

Dimethyltryptamine..........M2

Disorders of Glutamate..........16, W200

Disparities..........T168

Dissociation..........W140

DLPFC..........M80

DNA Methylation..........1.3, M16, M29, M32, M122, T183, T271, W110, W144

Dog..........M162

Dopamine..........6.3, 9.1, 42, 61.4, M30, M135, M183, M201, M205, M207, M212, M234, M241, M250, M268, M279, T2, T32, T184, T200, T235, T264, T267, W43, W66, W151, W160, W184, W214, W223, W232, W240

Dopamine (D2, D3) Receptors..........T114, T201, T239, T245, W69, W189

Dopamine 2 Receptor..........T18, T210

Dopamine 3 Receptor Imaging..........T239, W109

Dopamine Agonists..........M83

Dopamine D3 Receptors..........M239, M254

Dopamine Receptors..........M273

Dopamine Release..........W109

Dopamine System..........M91

Dopamine Transporter..........M270, W58, W225, W242

Dopamine-Deficient Mice..........W214

Dopaminergic Modulation..........T241

Dopaminergic System..........31.4, 33.2, T109

Dorsal Striatum..........16.2, M66

Dorsolateral Prefrontal Cortex..........31.2, M171, M216, W201

Dose-Response Analyses..........2, 2.3, M276

Downregulation..........50.4

DREADD Receptor..........W240

DREADDs..........42.3, T178, W69

Drebrin..........W250

Drug Abuse..........T264, W251

Drug Addiction..........20, 37, 50, 50.1, 53.2, T43, T229, T276, W273

Drug Cues..........T276

Drug Development..........M207

Drug Discovery..........M207

Drug Discovery - New Approaches..........25.1, T175

Drug Discovery/Development..........W193

Drug Liking..........T166

Drug Mixtures..........W234

Drug Relapse..........T261, W168

Drug Side Effects..........W221

Drug Use..........M219

D-Serine..........W165, W175

DSM-5..........T208

Duration of Untreated Psychosis..........27.3, 61.1, 61.2, 61.3, 61.4

Dynamical System..........13.1

Dynorphin..........M240, T142, T277

Dysphoria..........M25

E/I Imbalance..........17.3

Early Auditory Information Processing..........T199

Early Detection..........47, W44

Early Identification of Risk..........M37, T225, W33

Early Intervention..........47, 61

Early Life Stress..........1.2, 29.2, 46.1, T11, T38, T138, W27, W159

Early Psychosis..........27.3, M189, T208

Early Rearing..........55

Eating..........M59, M125

Eating Disorders..........M58, M61, T100, W54, W55, W57, W58

Ecological Momentary Assessment..........M4, M81

Education..........39

EEG Biomarkers..........10.1, 56.4, 57.1, M26, M47, M72, M104, M163, T110, W126, W174

EEG/ERP Electrophysiology..........15, 19.2, 56.3, 60.2, 60.4, M47, M117, T181, T192, T205, T216, T275

Effective Connectivity..........W59

Efficacy and Safety..........41.4

Effort-Cost Benefit Task..........33.1, T187, W108

Eicosanoids..........W90

Electric Field Modeling..........T145, T151

Electroconvulsive Therapy (ECT)..........7.4, M98, M103, T114, T130, T144, T151, W100, W102, W142

Electroencephalography (EEG)..........10, 24.1, 50.2, 56.2, T85, W44, W190

Electron Microscopy..........W277

Electronic Cigarette (E-Cigarette)..........T81

Electrophysiology..........3.2, 3.4, 37.3, 56, M142, M240, M258, M271, T2, T12, T139, T152, T211, T273, W86, W268

Emotion..........M81

Emotion Cognition Integration..........T118

Emotion Modulation..........4, T4

Emotion Processing..........M86, T275

Emotion Recognition..........W222

Emotion Regulation..........49.4, 50.2, M218, T100, T118, W20, W40

Emotional Memory..........W153

Emotional Pain..........43.1

Emotional Processing..........T71, W103

Emotional Regulation..........29.2, T9, T21, T30

Emotional Stress..........9, T84

Endocannabinoid..........16.2, 41.1, 41.2, 41.3, M8, M145, M275, M282, T68, T98, T99, W196

Endogenous Opioids..........W124

Endophenotype..........M174, M214, T213

Engram..........53, 53.4

Environmental Enrichment..........M229

Epidemiology..........T153, W146

Epigenetic..........1.2, 1.3, 46, M16, M152

Epigenetic Regulation..........T277

Epigenetics..........1, 6.1, 10, 10.3, 20.4, 46.1, M18, M32, M69, M269, T26, T38, T48, T60, T183, T230, T231, T278, W27, W144, W196, W265

Epilepsy..........42.1, M152

ERK..........W167

ERP..........19.3, T199

Error Processing..........M11

Errors..........W203

Escitalopram..........M82, M88

Esketamine..........W76, W93, W104, W107

Estradiol..........44.3, W72, W98

Estrogen..........44.1, 44.2, W247

Estrogen Synthesis..........44

Ethanol..........54.1, M230, W263

Ethical Issues..........45

Ethics..........45.1, 45.3

Event-Related Potential..........19.3, 60, T42, T220, W183

Excessive Sleepiness..........M222

Excitabilty..........9, M177

Excitation-Inhibition Balance..........T142

Excitatory Synapses..........W274

Executive Function..........29.4, M5, M50, T17, T57

Executive Network..........61.3

Exosome..........20.1

Expectation Bias..........M265

Experience Dependent Plasticity..........W40

Experimental Design..........M265

Experimental Medicine..........T187

Experimental Therapeutics..........T171

Exploration..........T69

Exposure Therapy..........4.4, T3, T8

Exposure-Response Model..........T263

Expression Quantitative Trait Loci..........T280

Extended Amygdala..........55.1

Extended Release Formulations..........35, 35.1

Extended Reward Network..........37.4

Extended Social-Affective Default Network..........W38

Extended-Release Depot..........T209

Extended-Release Naltrexone..........35.2

Externalizing Disorders..........29.4

Extinction..........4, T53

Extinction Learning..........W268

Eye-Tracking..........T85

F-18 PET Imaging..........31.3

FAAH..........41, T5

Face Emotion Processing..........M182, T65

Factor Analysis..........W249, W267

Familial Risk..........T24, T37

Familiality..........M174

Fast-Acting Antidepressant..........17, 17.2, 46.1, M131

Fatty Acid Amide Hydrolase..........41.1, 41.3

Fatty Acid Amide Hydrolase Inhibitor..........41.4

Fatty Acids..........W90

Fear..........4, M134, T194, W39

Fear Conditioning..........4.2, 53, 53.3, 53.4, T71, W7, W10

Fear Extinction..........4.1, 4.4, 41, 41.3, M12, T70, T178, W9, W10

Fear Generalization..........M23, W12

Fear Memory..........M13, M145, W7

Fear of Flying..........T8

FEAST..........W142

Feature Combination..........7.3

Feature Selection..........T271

Feeding..........30.2

Feeding Behavior..........M55

Female..........38.1, W122, W135

Fetal Brain Development..........W52

Fetal Neurobehavior..........W50

Fine Mapping..........W239

First Episode Psychosis..........61, 61.2, 61.4, M189, T197, W183, W195

First Episode Schizophrenia..........42.3, 52.1, 61.3, W204

FKBP5..........T38

Fluorodeoxyglucose..........M157, M179

fMR1 KO Rat..........W192

fMRI Biomarkers..........10.2

fMRI Faces Paradigm..........M114

fMRI Functional Connectivity..........12.1, 55.2, M49, M96, M133, M139

fMRI/Imaging Genetics..........M85

FMRP..........M194

fMRS..........T186

Focal Electrically Administered Seizure Therapy..........W142

Folate..........W205

Forced Swim Test..........W119

Forebrain..........55.1

Fractional Anisotropy..........M165

Fragile X..........T219

Fragile X Syndrome..........56, 56.1, 56.2, 56.4, W167, W192

Frontal Cortical..........M159, T188

Frontostriatal..........T137

Frustration Tolerance..........T9

Frustrative Non-Reward..........W136

Functional Capacity..........T182, W172

Functional Connectivity..........4.3, 25.4, 47.4, 55, M223, T196, W21, W38, W166, W229, W260

Functional Genomics..........T203

Functional Impairment..........5.1, M54, M109

Functional Magnetic Resonance Imaging (fMRI)..........4.3, 5, 5.3, 7, 10, 10.2, 12.1, 17, 24.1, 24.4, 29.3, 33.1, 33.3, 36.2, 49.1, 49.4, 60.3, M6, M11, M26, M44, M58, M83, M125, M127, M134, M139, M141, M151, M171, M173, M180, M197, M227, M252, M259, M266, M272, M276, T4, T14, T21, T50, T82, T86, T102, T105, T118, T120, T143, T147, T150, T179, T194, T216, T238, T240, T259, T276, W19, W35, W54, W56, W60, W61, W63, W74, W103, W111, W131, W170, W191, W200, W201, W226, W233

Functional Neuroimaging..........3.4, 5.3, 7.1, 12, 49, M46, T233, T254, W13, W37, W98

Functional Organization..........16.1

Functional Outcomes..........T221

Functional Selectivity..........W193

Functioning..........M211

GABA..........17.3, 17.4, M12, M62, M148, T59, T142, W248

GABA MRS..........W35

GABA Neuron..........T252

GABA Transmission..........M49, T52, T176, T243

GABAA..........W167

GABA-A Receptors..........9.2, M108, T141, T258, W116

GABAergic Cells..........W34

GABAergic Circuitry..........33.2, 40.3, T23

GABAergic Interneurons..........19, 19.4, 25.3

GABRA2..........T251, T265

GAD65 mRNA..........M62

GAD67 mRNA..........M62

Galantamine..........W141

Galantamine-Memantine Combination..........W220

Gambling..........W69

Gamma Oscillation..........40.3, 56.1, T212

GCF21..........M162

Gender Differences..........T161, T239

Gender Dysphoria..........W226

Gender Identity..........W226

Gene Co-Expression..........M193

Gene Editing..........45.3

Gene Expression..........1.1, 54.3, 59, 59.2, M13, M111, M136, M251, T60, T279, W208

Gene Manipulation..........45.1

Gene Regulation..........T38, W82

Gene X Environment Interaction..........M190

Gene-Environment Interaction..........1.4, M171

Genetic Architecture..........T67

Genetic Mouse Model..........43.2, T211, W42

Genetic Risk..........M193

Genetic Risk Factor..........6.2, T241

Genetically Modified Model..........45.2

Genetics..........21, 26, M187, T39, T60, T90, T201, T202, W276

Genome Editing..........45.2

Genome-Wide Association Study (GWAS)..........M85, M88, M92, M99, M188, M244, T191, T213, T265, T280, W101, W145, W148, W238, W239

Genomics..........T119, T202

Geriatric..........W4

Geriatric Depression..........W102

Ghrelin..........T259

Global Assessment Of Functioning (GAF)..........M208

Global Changes..........M54

Global Mental Health..........34

Global Outreach..........39

GLT-1..........W254

Glucocorticoid Receptor..........T25, W36

Glucocorticoid Receptor Gene..........M37

Glucocorticoids..........M275, W158

Glu..........N2BW168

Glutamate..........14.3, 16.3, 42, 47.2, 47.4, 52.1, 61.4, M76, M100, M165, T186, T200, W140

Glutamate GABA..........17, 19, 52, 52.2, T47

Glutamate Homeostasis..........16.1, M281, W254

Glutamate Receptor Activity..........T133

Glutamate Transport..........M281

Glutamatergic Synapses..........M185, M194

Glutamine..........M71

Glutathione..........M176

Glycosylation..........T185

Glymhatic Clearance..........M156

GLYX-13..........T79, W75

Goal Maintenance..........M186

Goal-Directed Behaviors..........M66

Golden Hours..........51.2

Gonadal Hormones..........48

GPCR..........25.1, 43, T31, T146

GPS..........T50

Graph Theory..........T143, T238

Gray Matter Volumes..........M42, T207

GT-tg Mouse Model..........T97

Guanfacine..........T54, T182

Gut Microbiome..........M138, M237, W112

Gut Microbiota..........W71

Gut-Brain Axis..........T99, T259, W71

GWAS LOCI..........T35

Habenula..........38.4, M85, T231

Habit..........T250

Habitual Behavior..........59.4

Habituation..........W74, W130

Hallucinogens..........M274

Haloperidol..........W214

HAM-D..........W97

Healthy Individuals..........31.4

Healthy Subjects..........M5, T190

Heart Rate..........M153, W272

Heart Rate Variability..........W259

Hedonic Ingestion..........T164

Hemodynamic Response Function..........M161

Hepatitis C..........M257

Heritability..........T67, W101

Heroin..........M249

Heroin Self-Administration..........W87

Heterogeneity..........W89

High Fat Diet..........32.2, W118

High Risk Psychosis..........11.4, 13.2, 27.1

Higher Level Cognition..........3, 3.2

Hippocampal Subfields..........M27, M103, W161

Hippocampal Volume..........61, 61.2, W161

Hippocampal-Prefrontal..........T178

Hippocampus..........20.2, 44.3, 47, 47.2, 47.3, 47.4, 53.1, 53.2, 53.3, M23, M98, M122, M169, M224, M248, T19, T66, T226, T228, W2, W10, W45, W159, W161, W275, W277

Hippocampus-mPFC Pathway..........19.1

Hispanic/Latinos..........T168

HIV..........32.3, M140, T27, T227, T233, W264

HIV-Associated Neurocognitive Disorder..........32.3, T97, W73

HNK..........W106

Homeostasis..........21, 21.1

Homeostatic..........T219

Homeostatic Plasticity..........14.2, W274

Hormone..........48.3

HPA Axis..........T25

Human Brain Imaging..........31.3, 46.3, M127, M239

Human Clinical Trial..........56.4, M113, T246

Human Connectome..........7, 7.1

Human Genetics..........34, M80, M278, T76, W88, W242

Human Neuroimaging..........4.2, 12.2, 15, 23.2, 24, 24.1, 24.3, 27.1, 33, 37.4, 49.2, M35, M68, M78, M239, M242, T17

Huntington's Disease..........16, 16.2, W70

Hydrocortisone..........51.2, W9

Hydroxynorketamine..........M132, W129, W135

Hyperalgesia..........M160

Hypersexual Disorder..........W225

Hypnosis..........W53

Hypothalamic-Pituitary-Adrenal Axis..........T59, W100

Hypothalamus..........38.1, 38.3

Hypoxia..........M2

IFITM..........M204

Imaging..........61.4, M166

Imaging Genetics..........W186

Immobility..........W143

Immune..........T127

Immune Biomarkers..........58, T84, W50

Immune Markers..........8, M164, M204, M213, M215

Immune Modulation..........M262

Immune System..........M170

Immunohistochemistry..........W185

Impulse Control..........T125

Impulsiveness..........M67

Impulsivity..........M44, M66, M136, M151, M218, M272, T100, T109, T198, T240, W55, W62, W65, W67, W68, W69, W232, W238

Imputation..........T60

In Vivo..........T224

In Vivo Calcium Imaging..........30.3, M120, M126, W11, W12

In Vivo Imaging..........30, 32, W64

Inattentive Symptoms..........W55

Inbred Mouse Strain..........21.4, T61

Incentive Motivation..........M250, M271, W241

Incubation..........14

Incubation of Cocaine Craving..........14.1, 14.2, 14.3

Individual Differences..........12.1

Individual Variability..........T151, T243

Indoleamine 2,3-Dioxygenase..........T135

Infant..........29.1, W50

Infection..........W215

Inferior Frontal Gyrus..........M59

Inflammasome..........M115

Inflammation..........13.2, 22, 22.2, 32, 44.4, 58, 58.2, M3, M71, M90, M93, M101, M112, M129, M166, M189, M237, T26, T46, T94, T140, T55, T135, T167, W71, W90, W215

Inflammatory Cytokines..........22.1, 58.4, T195

Inflammatory Disturbances..........W217

Inflammatory Markers..........16.1, 22.3, 32.3, M213, W172

Infralimbic Cortex..........W268

Inhibitory Control..........M11, M59, W65

Inhibitory Synaptic Transmission..........T141

Innate Alarm System..........W25

Innate Immunity..........M1

Inpatient..........M90

Insight..........W181

Insomnia..........T27

Instrumental Learning..........T262

Insula..........12, 12.1, M94, M125, M240, T4, T233, T255, W52

Insula Connectivity..........12.3, 12.4, 14.4

Insulin Resistance..........46, 46.1, 46.3, T28, T137, T138, W212

Insulin-Like Growth Factor 1..........M31

Integrative Health..........M225

Interim Treatment..........35.3

Interleukin-1..........T52

Interleukin-33..........M137

Internalizing Disorders..........T89

Internet..........57.2

Interneurons..........59.3, M209

Interoception..........T102, T157, T233, W56

Interpersonal Conflict..........T71

Intracranial Self-Stimulation..........T260

Intransal..........M28

Intravenous Administration..........M97

Intravenous Drug Self-Administration..........M280, W230

Intrinsic Excitability..........W274

Intrinsic Period..........40.1

Ion Channels..........W198

Iowa Gambling Task..........M264

Iron..........T253

Irregular Sleep/Wake Rhythm Disorder..........M220, M221

Irritability..........24, 24.3, T9, T14

Ischemia-Reperfusion Injury..........M2

JDTic..........M224

Joint Independent Component Analysis..........T216

JZP-110..........M222

Kalirin..........T222

Kappa Opioid..........W157

Kappa Opioid Receptor..........43.4, M240, M268, T124, T277, W5, W266

Ketamine..........2, 2.1, 2.2, 2.3, 2.4, 16.4, 17.2, 53.3, M28, M77, M87, M95, M96, M97, M100, M106, M107, M116, M121, M130, M132, T79, T111, T144, T162, T205, T212, T247, W20, W89, W92, W103, W106, W107, W122, W135, W140, W151

Kinome Array..........16.3

KO mice..........W281

Kv..........3 Channels..........42, 42.2, 59.3

Kynurenic Acid..........M100, T77, T192, W176

Kynurenine Pathway..........M82, T77, T135, T226, W93, W220

Kynurenines..........M101

Lamotrigine..........T123, W161

Language..........W21

Large Scale Networks..........12.4, M46, T147

Late-Life Depression..........M86, M99, T1, T176, T177

Latency of Acoustic Startle..........W211

Latent Class Analysis..........T165

Lateral Habenula..........W64, W132

Lateral Hypothalamus..........W11

Lateral Orbitofrontal Cortex..........T98, T106

Lateral Septum..........M23

Learning..........W133

Learning and Memory..........T186, W247, 53.2

Learning Health System..........W137

Left-Truncation..........M265

Leukocyte Telomere Length..........W110

Leukocytic miRNA..........13.1

LH..........W106

Life Stress..........T56

Light Therapy..........T6, T134

Limbic Cortex..........M94

Linkage..........W239

Linked ICA..........W256

Lipid Rafts..........T146

Lipids..........T278, W88, W172

Lipopolysaccharide..........M93

Lithium..........M52, T112, T160, W96

Lithium Response..........M123, W111

Local Field Potentials..........M55

Locus Coeruleus..........12.3, M258, T134, T158

Long Noncoding RNA..........20, 20.2, 20.4

Long Term Potentiation..........60, 60.1

Long-Acting Injectable Antipsychotics..........M199, T156, W85

Longitudinal..........57.2, T223

Longitudinal Analysis..........T78, W14

Longitudinal Imaging..........11.1, 11.2, M43, W201

Longitudinal Study..........M22, T39, W183

Long-Term Safety..........T209

Long-Term Treatment..........M95, M208

Long-Term Trial..........T263

Loss..........W123

Low Birth Weight..........M155

LPS..........M77

Lumateperone..........M76

Lurasidone..........T78, W121, W172

Macaque..........29.2, M162

Machine Learning..........5, 5.1, 18.3, 52.4, 57, 57.2, 57.3, M42, M55, M104, T155, T163, T271, W229

Machine Learning Clustering..........T121

MADRS..........M110, T29, W104

Magnetic Resonance Imaging (MRI)..........11.4, 23.1, 27.2, M25, M27, M42, M53, M150, M200, M205, M257, T112, T116, T136, T180, T253, W128, W149, W271

Magnetic Resonance Spectroscopy..........M12, T95, T123

Maintenance Treatment..........M95

Major Depression..........T128

Major Depressive Disorder (MDD)..........2.4, 10.4, 17, 24.4, 33.3, 49.1, 49.2, 49.3, 57.1, M20, M72, M79, M82, M103, M104, M108, M112, M124, M128, M256, T22, T56, T73, T115, T141, T143, T145, T148, T157, T234, W40, W79, W80, W84, W95, W102, W103, W109, W117, W120, W124, W128, W132, W138, W140

Manganese..........T185

Mania..........W78, W125

Marijuana..........M252, M256, M276, M282, T234, T268, W243

Marijuana Policy..........W236

Marmoset..........45.2

Maternal Behavior..........T138, W156

Maternal Depression..........M266, W52

Maternal Immune Activation..........8, M176, M198, T91, T108, W217

Maternal Sensitivity..........T65

Maternal Separation..........M45

MDPV..........W230

Mechanism of Action..........2, M96, M98

Medial Forebrain Bundle..........M110

Medial Prefrontal Cortex..........37.1, M12, M17, M24, M48, M209, T211, T258, W62, W154

Medication..........51.1, W224

Medication Development..........M270

Mediodorsal Thalamus..........3.1, 37.1

Medium Spiny Neuron..........W248, W261

MEF2C..........M194

MEG..........47.1, M191

Memory..........3.3, 4, 47.3, 53, 53.3, 53.4, T15, T132, T175, W2, W208

Memory Consolidation and Extinction..........51

Memory Encoding and Retrieval..........50.1, M141, W12

Memory Loss..........W3

Memory Reconsolidation..........4, 4.1, 4.4, M277, T8

Menopause..........W2, W3

Mental Health Service Use..........57.4

Mentalizing..........W210

Mesolimbic Circuitry..........T139

Mesolimbic Reward Circuitry..........T279

Meta-Analysis..........61.1, M11, M263, T58, T77, W13, W19, W24, W147, W151, W186

Metabolic Function..........W177

Metabolic Safety..........T189

Metabolic Side Effects..........M200, M217, T210

Metabolism..........W263

Metabolites..........T129, T224

Metabolomics..........T119, W92, W212

Metabotropic Glutamate Receptor..........46.1, T237, T249, W253

Meta-Cognition..........W181

Methadone Maintenance Treatment..........W259

Methamphetamine..........14.4, M228, M242, T253

Methionine..........W208

Methohexital..........T144

Methylphenidate..........T63

Mexican Americans..........W276

mGlu..........5M154

mGlu..........R5 Receptors..........M147

Mice..........17.1, T12, T256

Microbiota-Gut-Brain Axis..........W107

Microdialysis..........W108

Microglia..........22.2, 58.1, 58.2, T148, T177, W227

Microglia Dystrophy..........54.1

Microglia Priming..........54.1

Microglial Activation..........M230, W105, W227

MicroRNA (miRNA)..........6.1, 13, 13.1, 13.3, 20, T48

Microtubule..........M203, W207

Migraine..........M160

Mild Cognitive Impairment due to AD..........M50, M52, W184

Mild Traumatic Brain Injury..........51.3, M157

Mindfulness..........M18

Minocycline..........M213

Mismatch Negativity..........19.4, M214, T42

Mitochondria..........T113, T230, W169

Mitochondrial DNA..........W110, W159

Mitochondrial Dysfunction..........W73

Mitochondrial Function..........T204

Mixed Features..........W81

MMN1..........9.3, T199

MMP9..........40.3

Mobile Technology..........T80

Model-Free and Model-Based Learning..........57.2

Moderators..........T87

Molecular Mechanisms..........51, M262, T229

Monetary Incentive Delay Task..........T187

Monoamine Oxidase A..........M29, T180

Monoamines..........T152

Mood..........21.3, 48.3

Mood and Addiction..........W244

Mood Disorder..........11.1, 11.4, 16, 16.4, 33, 40, 46.2, 49, M102, M111, T63, T132, T160, W15

Mood Disorder Subtypes..........M70

Morphine..........M279, T244, W257, W273

Mortality..........M181

Motivation..........30, 30.1, 43.4, T267, W178

Motivational..........T122

Motor Activity..........21.1

Motor Behavior..........W34

Mouse Behavior..........M279

Mouse Model..........22.2, M34, M185, M221, T19, T260, W159

mPFC..........W16, W64

MPTP..........31.1, W162

MR spectroscopy..........M40, W200, W263

MR-PET..........M253

mtDNA..........T204

mTOR..........M132

mTORC1..........M130

Mu Suppression..........W174

Multi-Episode Schizophrenia..........W221

Multi-Modal..........W256

Multimodal Neuoimaging..........52, 52.4, T163

Multi-Site MRI..........W256

Multivariate Connectome-Wide Association Study..........M39

Mu-Opioid Receptor Agonist..........T166

Mu-Opioid Receptors..........25.2, 43.1, M231, W119, W233, W239, W244, W255, W281

Muscarinic Acetylcholine Receptor..........T193, W113

Muscarinic Receptors..........W47

Mutation..........W164

MVPA..........W147

Myelin..........M203, T61

N-Acetylaspartate..........M176, T95

N-Acetyl-Cysteine..........T29

Naltrexone..........35.1, M260, T251, W87

Narcolepsy..........M222

Negative Affect..........43.4, W266

Negative Symptoms..........M188, T190, T195

Neocortical Hyperexcitability..........56, 56.1

Neonatal..........11

Network Analysis..........M124, M197, T143, W19

Networks..........23.1

Neural Activity..........M261

Neural Circuitry..........14, M84

Neural Circuits..........30, 38, 38.1, 43.3

Neural Network Connectivity..........M41

Neural Oscillations..........M186

Neural Plasticity..........60.3, M91

Neural Stem Cell..........M74

Neural-Cardiac Interface..........50.4

Neuregulin-3..........20.2

Neuroactive Steroid..........W116

Neuroanatomy..........W134

Neurobehavioral Disorders..........30.4

Neurobiology..........48.1

Neurocircuitry..........W57, W149

Neurocircuits..........M241, W66, W86

Neurocognition..........52.4, W206

Neurocognitive Functioning..........M174, T165

Neurodegeneration..........M213, W168, W169, W280

Neurodegenerative Disease..........31.1, T155, W164

Neurodevelopment..........1.2, 27, 29.2, M176, W149

Neurodevelopmental Disabilities..........56, 56.3

Neurodevelopmental Disorders..........56.1, M194, W28, W146

Neuroendocrine..........M1

Neuroendocrinology..........51.3, M34, T138

Neurofilament..........M203

Neurogenesis..........M164, W20

Neuroimaging..........5, 7.4, 11, 27.2, 28.2, 50.3, M109, W57, W173

Neuroimmune..........54.3, M230, T52, W280

Neuroimmune Interaction..........M262

Neuroinfection..........T161

Neuroinflammation..........16, 22.4, 32.2, 40.3, 46, 46.2, 54, 54.1, 54.2, 58.1, 58.3, M189, M198, M217, M253, M281, T29, T33, T161, T172, T281, W36, W105, W270

Neuroleptic Malignant Syndrome..........W163

Neurological Disorders..........M102

Neuromarkers of Illness..........7.2

Neuromodulation..........18, 18.2, 33, 33.4, 36, M104, T31, T128, W53

Neuronal Activity..........3, 3.1

Neuronal Biomarkers..........50

Neuronal Culture..........W75

Neuronal Ensemble..........50.1

Neuronal Epigenome..........T91

Neuronal Maturation..........W243

Neuropathic Pain..........25.3

Neurophysiology..........M241, T125

Neuroplasticity..........60, 60.4, M10, M189, T56, T101, W197, W275

Neuropsychiatric..........22.4

Neuropsychiatric Disorders..........6.2, T220

Neuropsychiatry..........M159, W148

Neuropsychology..........M81, M206, T86, W102, W243

Neuroscience Driven Nomenclature..........39

Neurosteroid..........T169

Neurosurgery for Psychiatric Disorders..........18, 18.1

Neurotechnology..........T97

Neurotransmitter Co-Release..........W223

Neurotransmitters..........T235

Neurotrophins..........T140

Neurovascular..........M139, W185

New Drug Development..........W199

Next Generation Sequencing..........M74, M123

NFkB..........M204, W36

Nicotine..........20.2, M234, M260, M280, T81, W141, W203, W232, W264

Nicotine Addiction..........M281, T44, T54, T241, T256, W269

Nicotine Dependence..........12.1, 12.4, 20.1, M33, M243

Nicotinic Acetylcholine Receptors..........M234, M278, T44

NMDA..........M28, M76

NMDA Antagonists..........M96, T162, T198, W168, W200

NMDA Glutamate Receptors..........T282

NMDA Receptor..........14.1, 19.3, 42, 42.1, M185, T199, T211, T212, W99, W163, W165, W175

Nociceptin..........30.2, 30.4, W245

Non-Coding..........M202

Non-Coding RNA..........10.4, 20.3

Non-Human Primate (NHP)..........31.3, 45, 45.2,45.3, M10, M143, M176, T272, W20, W162,W255

Non-Human Primate Model..........45.1, M198, W131, W245

Non-Medical Use..........W258

Non-Pharmacological Therapy..........T62

Nonverbal Reasoning..........M41

Noradrenergic System..........M14

Norepinephrine..........M30, W15

Novel Endpoints..........T269

Novel Targets..........T130

Novel Therapeutics..........M79, T62, T134, T169, T260

Novel Tool..........M67, M248

NTRK3..........M10

Nucleus Accumbens (NAA)..........9.1, M126, M236, M278, M279, T53, T142, T229, T267, T282, W16, W62, W67, W68, W136, W250, W261

Nucleus Accumbens Core..........14.1, T51

Nucleus Accumbens Shell..........M65, T20, T252, W154

Obesity..........46.2, T18, T30, T137, T164, W60, W61

Obsessive-Compulsive and Related Disorders..........M68

Obsessive-Compulsive Disorder (OCD)..........18, 18.1, 18.2, 18.3, M9, M11, M27, M28, M161, T3, T67, T76, T79, T87, T105, W6, W8, W16, W18, W26, W63

Obsessive-Compulsive Symptoms..........T165

Obstetric Complications..........1.4

Occupancy..........W189

Olanzapine..........T214

Olfaction..........M134

Olfactory..........T198

Oligodendrocytes..........T173

Omega-3 Fatty Acid..........T94, T149, T197, W29

One-Carbon Metabolism..........W208

Opiate..........M140, M249, M266, T244, T271, W250

Opioid..........25, M232, M235, M272, W94, W234, W251, W266

Opioid Agonist Treatment..........35, 35.1, 35.4, M232, W228

Opioid Antagonist Treatment..........35, 35.1, M255

Opioid Dependence..........25.2, 35, 35.2, 35.3, 35.4, M259, T263

Opioid Overdose..........W281

Opioid Receptors..........43.3, W80

Opioid Side-Effects..........25.1, 25.2

Opioid System..........25.1

Opioid Withdrawal..........M235

Optochemogenetics..........43

Optogenetics..........12, 19.1, 30, 30.1, 30.3, 53.1, M24, M64, M241, M271, T12, T109, T158, T174, W66, W235

Orbitofrontal Cortex (OFC)..........M109, M261, W136

Orexin..........M247

Orexin Receptor Antagonist..........M220, M221, M247, T158

Oscillation..........19, M191

Oscillatory Activity..........3, 42.1, 57.1

Osteoprotegerin (OPG)..........16.4

Overdose..........W234

Oxidative Stress..........40.3, 46, M73, W121

Oxytocin..........M134, T194, T218, T270, W156, W174, W210, W279

Oxytocin and Addiction..........W278

P2X7..........M113

P300..........W179

PACAP..........W23

Pain..........25.1, 43.3, 43.4, M38, M75, M160, M232, T162, W147, W228, W255

Pain Sensitivity..........T64

Paraventricular Nucleus of the Thalamus..........W130

Parkinsonism..........T170

Parkinson's Disease..........45, T171, T172, W162, W164, W176, W184

Parkinson's Disorder..........T192

Partial Agonist..........T245

Parvalbumin..........40.3, M209

Parvalbumin Interneuron..........17.1, 42.2, T36

Parvalbumin Neurons..........M48, T212, W121

Patch..........W49

Patch Foraging..........T32

Pathalogical Gambling..........T264

Pathophysiology..........47.2

Pathway Analyses..........16.3

Pathways..........21.3

Patient Functioning..........M208

Patient Reported Outcomes..........W76

Pavlovian..........T262

Pavlovian Conditioning..........M242, T101, W15, W231

PDE10A..........W199

Pediatric..........T162, W30

Pediatric PTSD..........M43

Pentosan Polysulfate Sodium..........T46

Perceived Stress..........W259

Perfusion..........23.1, 49.2, M60

Periaqueductal Grey (PAG)..........W25

Perinatal Brain Injury..........22.4

Perinatal Stress..........22, W31

Perineuronal Net..........40.3, T255

Peripartum..........T65

Peripheral Blood Mononuclear Cells..........13

Personal and Social Performance (PSP)..........M208, M211

Personality..........M119, T21

PET Resting Metabolism..........M5

PET Tracer..........31

PharmacoBOLD..........W200

Pharmacogenetic Response..........M167

Pharmacogenetics..........M88, M144, T251, W127

Pharmacogenomics..........W127

Pharmacokinetics..........W113, W269

Pharmacology..........59.2, T90, W57, W204

Pharmacotherapy..........59, M144, M181, M280, T74, T249, T269

Phencyclidine..........W178

Phenotypes..........25.4, M235

Phenotyping..........23, 23.2

Phosphodiesterase 1 Inhibitor..........T172

Phosphodiesterase-4 (PDE4)..........T175

Phosphorus Magnetic Resonance Spectroscopy..........T181

Phosphorylation..........M196

Photometry..........30.1, M250

Physical Exercise..........W45

Placebo Response..........M262

Placenta..........1, 1.1, 1.2, 1.3, 1.4

Plasticity..........M105

Polygenic Risk Score..........1.4, 21.2, M37, M171

Polygenic Scores..........M168

Polymorphism..........W242

Polypharmacy..........T184

Population Genetics..........W148

Population Pharmacokinetics..........M199

Positive Allosteric Modulators..........42.1, M108, T193, W141

Positive and Negative Syndrome Scale..........T206

Positron Emission Tomography (PET)..........58.3, M148, M154, M201, T235, T239, W124, W233, W253, W266

Positron Emission Tomography (PET) Imaging..........42.3, 54, 58.4, 61, M7, M113, M135, M147, M239, M254, T16, T33, T45, T82, T133, T155, T237, T245, W1, W91, W105, W109, W157, W189, W270

Postmortem..........M128, T193, W213, W219

Postmortem Brain Tissue..........52.3, M136, M195, M196, T38, W96, W185, W198

Postmortem Human Brain..........M204, M216

Postpartum Anxiety..........W97

Postpartum Depression..........T2, W97, W116

Posttraumatic Stress Disorder (PTSD)..........4.3, 24, 24.4, 51, 51.1, 51.2, 51.3, 51.4, 53, 53.4, M1, M3, M12, M14, M15, M16, M18, M19, M20, M21, M22, M24, M25, M29, M30, M104, T6, T25, T60, T70, T72, T121, T143, T169, T225, T254, T270, W9, W14, W15, W19, W20, W22, W25, W74, W99, W112, W153

Pragmatic Analysis..........57

Prairie Voles..........M228

Pramipexole..........M83, W109

Prazosin..........M14

Precision Medicine..........18.2, T116

Precision Medicine for Depression..........16.1

Precision Medicine for Mood Disorders..........M113, T147, W137

Precision Psychiatry..........24.2, T121

Preclinical..........54, M220, W257

Prediction..........5.2, 24.4, 57, M21, T80

Prediction Error..........T42

Predictive Model..........5.1, M21, M133

Predictors of Response..........M97, T87

Prefrontal Circuit..........T196

Prefrontal Cortex..........3.1, 6, 14.3, 17.1, 29.4, 37.3, 59.3, M65, M105, M142, M275, T44, T236, W43, W171, W184, W262

Prefrontal-Amygdala-Connectivity..........M43, T12

Pregnancy..........1.1

Prelimbic..........T51, T52

Prematurity..........M155, T17

Premenstrual Dysphoric Disorder..........M74, T131, W72

Pre-Morbid IQ..........M168

Prenatal..........22.1, 22.2

Prenatal SSRI Exposure..........M122, W52

Prenatal Stress..........22.3, M138, W34, W158

Prepulse Inhibition..........T35, T215, W18, W206, W211

Prescription Drug Abuse..........W252

Prescription Opioids..........35.4, W275

Presynaptic Uptake..........W223

Preterm..........M155

Prevention..........51

Prevention of Alzheimer's Disease..........M51, M52

Primate Model..........W41

Probiotics..........W125

Prodrug..........W252

Progesterone..........W98

Prolactin..........M149

Prophylactic..........W92, W135

Prostaglandin..........44.4

Prostaglandin-Endoperoxide Synthase 1..........M216

Protein Interactions..........43.2

Protein Trafficking..........M196

Proteomics..........M196, T31

Proton Magnetic Resonance Spectroscopy..........M148, T47

PSD-95..........M185

P-Selectin..........T46

Psilocybin..........M274

Psychiatric Comorbidity..........T74, W244

Psychiatric Cross Disorder Risk..........W146

Psychiatric Disorders..........48, W92

Psychiatric Genetics..........W117, W225

Psychological Autopsy..........M136

Psychometric Properties..........26

Psychoneuroimmunology..........M262, W31

Psychopharmacology..........W218

Psychophysiology..........T8, W94

Psychosis..........27, 27.2, 28.4, M163, M172, M180, M205, M226, T181, T191, T234, W173, W179, W182

Psychosocial Stress..........25.4, T61, W143

Psychosocial Treatment..........T58

Psychosomatic Medicine..........M102

Psychostimulant..........6.1, T18, T237, W252

Psychotherapy..........51.3, M19

Psychotic Disorders..........T223, W146

Psychotropic Medications..........T204

PTEN..........T173

Puberty..........48, 48.1, 48.2

Punishment..........W262

Pupillometry..........W174

Purkinje Cell..........44.4

Pyramidal Neuron..........19

Quantitative Electroencephalography (qEEG)..........M158, T16

R-(-)-Ketamine..........W129

R-(-)-Norketamine..........W129

Radiotracer..........T239

Rage..........40.3

Randomized..........M79

Randomized Clinical Trial..........35.2, 41.4

Randomized Controlled Trial..........2.3, 44.1

Rapastinel..........M131, T79

Rapid Antidepressant..........M96

Rapid Antidepressant Effects..........M121

Rat..........T268, T272, W29, W87, W257

Rat Models..........M33, M249, T68

Reactive Astrocyte..........W165

Reactive Attachment Disorder..........M32

Real-Time fMRI Neurofeedback..........W171

Reappraisal Training..........W170

Receptor Activator of Nuclear Factor-kB Ligand (RANKL)..........16.4

Receptor Occupancy..........M154

Receptor Trafficking..........W233

Reconsolidation Intervention..........4.1

Recovery..........T150, W85

Refinement..........6.1

Regions of Interest..........M257

Regulatory..........W228

Reinforcement..........T252

Reinforcement Learning..........33.2, M57, W63

Reinforcement-Based Decision-Making..........T106

Reinstatement..........T231, W279

Rejection..........W124

Relapse..........14.4, M275, M281, T115

Relapse and Hospitalization..........W204

Relapse and Treatment Outcome..........M259

Relapse Prevention..........50, M238, W125

Relatives..........M163

Relevance for Outcomes..........61.1, T199

REM Sleep..........W95

Remission..........11.3, W85

Repetitive Behavior..........W160

Repetitive Transcranial Magnetic Stimulation (rTMS)..........M20, M75, M104, T95, T120, T147

Replication..........23

Reproducibility..........23

Research Domain Criteria (RDoc)..........T110, T157, W13, W17, W136

Residency Training..........39

Residual Symptoms..........T115

Resilience..........6.1, W4, W115

Respiration..........T73

Respiratory Depression..........25.2

Response Inhibition..........11.3, 37.4

Resting State..........M19, W260

Resting State Brain Imaging..........M256, W28

Resting State fMRI..........49.3, 61.3, M39, M49, M85, M243, T24, T163

Resting State Functional Connectivity..........6.3, 16.1, 17.4, 28, 28.3, 32.2, 33.4, 38.4, 48.1, 55.4, 59.4, 61, M20, M33, M41, M56, M78, M94, M106, M161, M182, M197, M278, T57, T132, T137, T179, T238, T242, W97, W150

Resting State Intrinsic Connectivity..........11.3, W190

Retina..........21.3, T45, T134, T235

Retrograde Tracing..........55.1

Rett Syndrome..........M31, T173

Reuptake Inhibitor..........M30, T103

Reversal Learning..........T106, W16

Reward..........38.2, 49.1, T10, T81, T101, T190, T240, T267, W98, W231, W241

Reward and Aversion..........T49, T260, W251

Reward Circuitry..........30.4, 40.2, M56, M60, M83, T158, T266, W114

Reward Devaluation..........T51

Reward Network..........T164

Reward Neural Circuitry..........29.3, 32.2, 33.3, 33.4, 48.2

Reward Prediction Error..........33.2, M58, W59

Reward Processing..........24.3, T122, T192, T241

Reward Sensitivity..........W178

Reward-Based Decision-Making..........12.2, 31.4, 33, 37.1, M57, W64, W154

Rhesus..........55.2, T205

Rho Family GTPase..........M131

RiboTag..........T117, W134, W156

Risk..........W14

Risk and Resilience..........M126, W40, W123

Risky Decision-Making..........M231, W232

Rivastigmine..........W49

RNA..........M202

RNA Binding Protein..........20.3

RNA Sequencing (RNA-Seq)..........43, 43.2, 59.1, M164, M193, M229, T11, T61, T117, W72, W156, W198

Rs..........10514299T266

Rumination..........W138

Safety..........W228, W269

Safety Context..........55

Salience Network..........M256, T15

Samidorphan..........T214, W87

SAPAP3..........W16

Scanner Harmonization..........7.2

Schizophrenia..........1.4, 6.1, 7.4, 8, 13, 13.3, 16, 16.3, 19.2, 19.4, 24, 24.2, 36, 36.2, 36.3, 42, 42.2, 44, 44.1, 47, 47.1, 47.3, 47.4, 60.2, 60.3, 61.1, M89, M164, M166, M169, M173, M175, M178, M181, M182, M183, M185, M186, M187, M190, M191, M192, M193, M195, M196, M198, M202, M204, M206, M208, M210, M212, M213, M214, M215, M216, M217, M226, T34, T35, T36, T39, T41, T42, T44, T46, T179, T182, T183, T184, T185, T186, T189, T192, T195, T196, T200, T201, T202, T203, T206, T209, T211, T212, T214, T215, T216, T218, T219, T220, T221, T222, W70, W108, W112, W172, W176, W177, W178, W180, W181, W186, W187, W188, W190, W196, W197, W198, W199, W201, W203, W205, W206, W207, W209, W210, W211, W212, W213, W215, W218, W219, W220, W224

Schizophrenia Databases..........W186

Schizophrenia Genetics..........21.2, T213

Schizophrenia Negative Symptoms..........T187

Schizophrenia Prodrome..........60.4, T208

Schizophrenia Subtypes..........M168, M188, T193

Schizophrenia-Like Behavior..........T43, W70

Schizotypal Personality Disorder..........T179

Schizotypy..........T194, W210

Screening..........W44

Seizure..........T160, W215

Self-Administration..........M228, M249, T259, W246, W268

Self-Other Processing..........T21, W54

Self-Perception..........W226

Self-Referential..........W61

Self-Regulation..........M39, M227, T13, T100

Semantic Priming..........T216

Sensitization..........M246, M279, T237, T264

Sensorimotor Gating..........T215

Sensory Gating..........W192

Sensory-Emotional-Memory..........W61

Serine Racemase..........W165, W175

Serotonin..........M30, M82, W43, W237

Serotonin 1A Receptor..........W120, W166

Serotonin 5-HT2C Receptor..........W67

Serotonin Reuptake Inhibitors..........T131

Serotonin Transporter..........M231, W120

Sex Differences..........1, 1.2, 27.1, 44.2, 44.3, 44.4, 48.2, 48.3, M34, M45, M61, M105, M135, M228, M233, M258, M267, M280, T28, T54, T84, T111, T117, T161, T226, T247, T268, T274, W2, W23, W31, W34, W36, W58, W60, W153, W237, W275

Sex Steroids..........22.1, 48.2, M53, M135, T22

Sexual Dimorphism..........38.1, M63, T124

Short-Term Clinical Studies..........M210

Short-Term Studies..........M211

shRNA..........W114

Side Effects..........T41

Sigma-1 Receptor..........M2

Signal Transduction..........43.2

Sign-Tracking..........W231

Simultaneous PET-MR..........W166

Single-Cell..........W158

SK Calcium-Activated Potassium Channels..........T20

Skin Conductance Responses..........T71

Sleep..........3.4, 21, 40, 40.1, 40.2, 40.4, M156, T228

Sleep Deprivation..........T219, T226, W132

Sleep Disturbance..........T225, T227

Sleep Spindles..........21.2, T16, W195

SLOS..........W51

Slow Waves..........T16, W195

Slow-Wave Sleep..........M44, W95

Smartphone-Based App..........M81, T232

Smoking..........T50

Smoking Status..........W209

snoRNA, miRNA and piRNA..........10.4

SNP..........T215

Social Anxiety..........M35

Social Anxiety Disorder..........T4

Social Behavior..........9.3, M48, M89, M138, M228, T2, T10, W41, W155

Social Cognition..........M197, M218, T194, W54, W181, W210, W222

Social Competence..........48.4

Social Cue Detection..........M173

Social Defeat Stress..........M71, M184, T139, W107

Social Deficits..........M249

Social Discrimination..........T15

Social Functioning..........T218

Social Interaction..........M26, M35, M137, M153, W43

Social Play Behavior..........44.4

Social Preference..........M173

Social Reward..........W38

Social Skills Training..........T218

Social Status..........W157

Social Stimuli..........W174

Social Stress..........M134

Sociality..........M162

Solriamfetol..........M222

Soluble Epoxide Hydrolase..........W90

Somatostatin..........19.3, M23, M209

Sonic Hedgehog Signaling..........W227

Spatial Navigation..........W194

Spiking Neural Models/Rate Models..........3.2

Splice Variants..........25.2

SSRI..........M36, T82, W17, W24

Staging..........5, 5.1, 5.2

STAI..........W97

STAR*D..........W101

Statistical Methods..........W89

Stem Cells..........45, W227

Stimulant..........W252

STN, W8

Stopping..........M64

Stress..........48.1, M73, M130, M162, M275, T26, W92

Stress Cascades..........W217

Stress Induced Depressive Behavior..........M116

Stress Models..........T127

Stress Reactivity..........M80, W237

Stress Resilience..........M116

Stress Response..........M164

Stress-Induced Reinstatement..........T54

Striatal Cortical Circuits..........W28

Striatum..........M142, T31, T101, T107, T233, T256, W5, W133, W160, W241

Structural MRI..........7, 7.1, 11.1, 11.2, 18.1, M32, W1

Structural Neuroimaging..........7.3, M43, T191, W6

Structure of Psychopathology..........6.4

Structure-Activity Relationships..........W230

Subchronic Ketamine Model..........42.3

Subcortical Shape Analysis..........T136

Subgenual..........M109

Subgenual Cingulate Cortex..........T151

Subjective Cognitive Decline..........W48

Subphenotypes..........T202

Substance Abuse..........28, 40, M223, W258, W259

Substance Use..........28.1, 28.2

Substance Use Disorder..........M227, M251, T157, W239

Subthalamic Nucleus..........M64

Subtypes..........57.3, M243, W260

Suicidal Ideation..........2.2

Suicidality..........T95, W93

Suicide..........2.1, 11.1, M85, M90, M97, M111, M187, T25, T130, T149, T208, W82, W88, W124

Suicide Behavior Severity..........M69

Superior Colliculus..........W25

Susceptibility..........W115

Susceptibility Genes..........1

Sustained Attention..........3.2, M146, T217

Sustained Threat of Shock..........55.4

Switch..........W185

Symptom Trajectory..........11.2

Symptom-Onset Treatment..........T131

Synapses..........8, M130, M164, M204, M213, M215, W175

Synaptic Aberrations..........7.4, M185, W70, W207

Synaptic Plasticity..........9, 14, 16.2, 17.2, T53, T98, W99, W130, W175, W261

Synaptic Protein Imaging..........W91

Synaptic Pruning..........T36

Synaptic Vesicle..........W223

Synchronized Transcranial Magnetic Stimulation (sTMS)..........T145

Synchrony..........47.1

Synthetic Opioids..........W281

Systematic Review..........W182

Systemic Inflammation..........M8, M125

Systems Neurobiology..........T196

TAAR 1..........W257

Tardive Dyskinesia..........M149, M183, T159, W152

Target Engagement..........M154

Task-Based Functional Connectivity..........M180

Tau..........T96, W48, W207

TCF4..........T173

Team Building..........34

Technology..........M226, T182

Teenage Onset..........T204

Telomere..........22.3, 46.3, T113

Temperament..........M119

Test Retest..........M180

Testosterone..........48.4

Thalamo-Cortical Interactions..........3, 3.4

Thalamus..........3.2, 3.3, W195

Thalamus - Reticular Nucleus..........3.4

THC..........41, T234, T236, T246

Therapeutic Trial..........T156

Therapeutics..........25, T96

Theta..........19.3, M17

Theta Burst Transcranial Magnetic Stimulation..........W53

Threat..........4.3, 29.3

Threat Context..........55, 55.2

Threat Faces..........24.3

Threat of Shock..........T126

Thyroid Hormone..........M13

Tianeptine..........43.1

Time Estimation..........M276

Timing..........T32, T34, W194

TMEM161B/MEF2C..........T266

TMS Targeting..........M6

TMS-EEG..........M15, W197

TNF-Alpha..........W82

Tobacco..........T50

Tobacco Smoking..........W209, W270

Tolcapone..........M159, M192

Tolerance..........M219

Toll-Like Receptors (TLRs)..........T108

Top-Down Control..........19.4, M146, T93

Touchscreen..........M146, T110, T272

Tract Tracing..........55

Tractography..........18.2, T154

Training..........19.3, 39, T199

Trajectory..........11

Trajectory Modeling..........M21

Transcranial Direct Current Stimulation (TDCS)..........36.2, 36.3, M59, T, W191

Transcranial Magnetic Stimulation (TMS)..........17.4, 24.1, 50.3, M6, M49, M158, M182, M223, T176

Transcription..........T183, W158

Transcription Factors..........W73

Transcriptome..........M70, M244, T230, 279

Transcriptomics..........M31

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)..........T73

Transdiagnostic..........5.2, 26, M133, M172, M223, W13

Transgenerational..........W31

Transgenic Mice..........30.3, W108

Transgenic Models..........45.2

Transition..........5.2

Translational..........48

Translational Approaches to Drug Development..........56

Translational Biomarker Development..........56.3, T129, W100

Translational Imaging..........32

Translational Medicine..........W199

Translational Models..........T69, W227

Translational Neuroscience..........29, 39, M117, M127, T50, W131

Translational Pharmacology..........M91, W15

Translational Research..........41.2, 54, T13, W31

Translocator Protein (TSPO)..........58, 58.1, 58.2, 58.3, 58.4, M115, W105, W217

Trauma..........M19, M73, T64

Trauma Exposure..........T65, W22

Traumatic Brain Injury (TBI)..........58.4, M159, T169

Treatment..........15, 18, 41.4, 51, W6, W182, W224

Treatment Access..........35

Treatment Adherence..........T156

Treatment Outcome..........52.2

Treatment Outcome Prediction..........49.2, 57.1, W229

Treatment Resistance..........M84, T128, W80

Treatment Resistant Depression..........10.2, M87, M95, M97, M110, M121, T11, T28, T75, W76, W100, W119

Treatment Response..........49.1, M57, M124

Treatment-Resistant Schizophrenia..........52.3

TrkB..........M123

TSPO and [11C]PBR-28 PET..........54.2, W270

Two-Photon..........37.1, M248, T31, T44

Type-2 Diabetes..........M1

Ubiquitination..........52, 52.3

Ultra High-Risk Youth..........W222

Unaffected Relatives..........M174

Vagus Nerve..........T99

Valbenazine..........M149, M183, T159, W152

Validation..........31.3

Valproic Acid..........T92

Varenicline..........M260, M280, W209

Vascular Endothelial Growth Factor..........T140

Vasopressin..........22.2, W41

Vasopressin 1A Receptor Antagonist..........W42

VC/VS..........W8

Venlafaxine..........M99

Ventral Hippocampus..........W11

Ventral Pallidum..........M271, T261

Ventral Striatum..........49.1, M234, T244, W123, W248

Ventral Tegmental Area (VTA)..........30.1, M246, M269, T158, T252, T257, T267, W64, W273

Ventrolateral Prefrontal Cortex..........T150, W205

Ventromedial Prefrontal Cortex..........48.4, W272

Verbal Memory..........M215

Vesicular Glutamate Transporter (VGLUT)..........W68, W223

Veterans..........M118, W153

Virtual Reality..........4.4, M248

Visceral Obesity..........M53

Visual Information Processing..........19.3, M215, T104, T220

Visual Perception..........T188

Visual Plasticity..........60.2, 60.3

Visuospatial Ability..........M41

Visuospatial Working Memory..........M204

VMAT2..........T224, W152

Voxel-Based Morphometry (VBM)..........M63, M156

Vulnerability..........W232, W263

Waitlist..........35.3

Weight Loss Treatment..........M60

White Matter..........11.3, 32.1, M155, W14, W187

White Matter Fractional Anistropy..........M179

White Matter Integrity..........W4, W202

Whole Exome Sequencing..........T76

Whole Genome Sequencing..........26

Whole-Cell Patch Clamp Recording..........W277

Williams Syndrome..........M41

Wistar Kyoto Rat..........M153, W119

Withdrawal..........20

Within Person Variance..........M175

Women..........32.3, M1

Women's Mental Health..........T56, T88, W22

Working Memory..........3.1, 19.1, 31, 31.2, 36.2, 36.3, M6, M209, T59, T236, T268, W194, W202, W205

Working Memory fMRI..........61.3, M184, W138

xCT..........W254

Young Adults..........M78

Youth..........M200

Zebrafish..........T35, T90

Zonulin..........M178

β-arrestin..........W193